• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.

作者信息

Cove Christina L, Hylek Elaine M

机构信息

Department of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA.

出版信息

J Am Heart Assoc. 2013 Oct 23;2(5):e000136. doi: 10.1161/JAHA.113.000136.

DOI:10.1161/JAHA.113.000136
PMID:24152980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3835217/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/3835217/0020f41bc60c/jah3-2-e000136-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/3835217/0020f41bc60c/jah3-2-e000136-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/3835217/0020f41bc60c/jah3-2-e000136-g1.jpg

相似文献

1
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.用于心房颤动、静脉血栓栓塞性疾病和急性冠状动脉综合征的卒中预防的新型口服抗凝剂的最新综述。
J Am Heart Assoc. 2013 Oct 23;2(5):e000136. doi: 10.1161/JAHA.113.000136.
2
The newer direct oral anticoagulants: a practical guide.新型直接口服抗凝剂：实用指南。
Clin Med (Lond). 2014 Apr;14(2):165-75. doi: 10.7861/clinmedicine.14-2-165.
3
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.新型口服抗凝剂用于心房颤动患者的疗效及安全性比较
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.
4
Target-specific oral anticoagulants: practice issues for the clinician.靶向口服抗凝剂：临床医生的实践问题
Hosp Pract (1995). 2014 Aug;42(3):48-61. doi: 10.3810/hp.2014.08.1117.
5
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.新型口服抗凝剂（达比加群、利伐沙班、阿哌沙班）与华法林治疗心房颤动患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24.
6
New agents to prevent strokes in nonvalvular atrial fibrillation.预防非瓣膜性心房颤动中风的新型药物
Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):44-6. doi: 10.14797/mdcj-8-3-44.
7
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.阿哌沙班、达比加群、利伐沙班和华法林预防房颤卒中的成本效益分析。
Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.
8
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.新型抗凝剂（达比加群、阿哌沙班、利伐沙班）用于预防房颤卒中。
Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001.
9
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
10
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.新型抗凝剂与华法林用于心房颤动卒中预防的比较
Cardiovasc Hematol Disord Drug Targets. 2014;14(1):79-86. doi: 10.2174/1871529x1401140724100642.

引用本文的文献

1
A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes.一种新型 LC-MS/MS 测定法用于定量检测去羧基凝血酶原及其在华法林诱导作用下的变化特征。
Clin Transl Sci. 2020 Jul;13(4):718-726. doi: 10.1111/cts.12757. Epub 2020 Mar 9.
2
Suicidal drug overdose following stroke in elderly patients: a retrospective population-based cohort study.老年患者中风后自杀性药物过量：一项基于人群的回顾性队列研究。
Neuropsychiatr Dis Treat. 2018 Feb 7;14:443-450. doi: 10.2147/NDT.S157494. eCollection 2018.
3
Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics.

本文引用的文献

1
Oral apixaban for the treatment of acute venous thromboembolism.口服阿哌沙班治疗急性静脉血栓栓塞症。
N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
2
Practical issues, limitations, and periprocedural management of the NOAC's.NOAC 的实际问题、局限性及围手术期处理。
J Thromb Thrombolysis. 2013 Aug;36(2):212-22. doi: 10.1007/s11239-013-0911-2.
3
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.在静脉血栓栓塞症中延长使用达比加群、华法林或安慰剂。
两家不同综合诊所华法林使用的疗效与安全性比较。
Anatol J Cardiol. 2017 Nov;18(5):328-333. doi: 10.14744/AnatolJCardiol.2017.7886.
4
The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study.土耳其不同地理区域的华法林治疗范围时间和出血并发症：WARFARIN-TR 研究的亚组分析。
Balkan Med J. 2017 Aug 4;34(4):349-355. doi: 10.4274/balkanmedj.2016.1617. Epub 2017 Apr 6.
5
A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.心房颤动与急性冠状动脉综合征关系的综述
Curr Emerg Hosp Med Rep. 2016 Sep;4(3):107-118. doi: 10.1007/s40138-016-0105-2. Epub 2016 Jul 6.
6
Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative management.围手术期静脉血栓栓塞性疾病及新型口服抗凝药的新作用：对围手术期管理影响的分析
Ann Card Anaesth. 2015 Oct-Dec;18(4):517-27. doi: 10.4103/0971-9784.166461.
7
ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.国际腹膜透析学会成人腹膜透析患者心血管和代谢指南 第二部分——各种心血管并发症的管理
Perit Dial Int. 2015 Jul-Aug;35(4):388-96. doi: 10.3747/pdi.2014.00278.
8
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.社区环境中接受华法林治疗患者的酒精滥用、遗传学与严重出血情况
Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):619-27. doi: 10.1002/pds.3769. Epub 2015 Apr 8.
9
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience.专门的儿科心脏抗凝计划的效用：波士顿儿童医院的经验
Pediatr Cardiol. 2015 Apr;36(4):842-50. doi: 10.1007/s00246-014-1089-x. Epub 2015 Jan 9.
10
Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides.设计因子 XIa 的别构抑制剂。硫酸五没食子酰葡萄糖吡喃糖苷相互作用的启示。
J Med Chem. 2014 Jun 12;57(11):4805-18. doi: 10.1021/jm500311e. Epub 2014 May 29.
N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.
4
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.利伐沙班用于急性病医学患者的血栓预防。
N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.
5
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.新型口服抗凝剂的实验室评估：方法适用性和不同凝血实验室间的变异性。
Clin Chem. 2013 May;59(5):807-14. doi: 10.1373/clinchem.2012.198788. Epub 2013 Feb 1.
6
Acute management of bleeding in patients on novel oral anticoagulants.新型口服抗凝药物治疗患者的出血急症管理。
Eur Heart J. 2013 Feb;34(7):489-498b. doi: 10.1093/eurheartj/ehs408. Epub 2012 Dec 7.
7
Apixaban for extended treatment of venous thromboembolism.阿哌沙班用于静脉血栓栓塞症的延长治疗。
N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.
8
Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.非瓣膜性心房颤动卒中预防的抗血栓治疗。
Lancet Neurol. 2012 Dec;11(12):1066-81. doi: 10.1016/S1474-4422(12)70258-2.
9
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.依房颤患者的卒中和出血风险评估，比较阿哌沙班与华法林的疗效和安全性：一项随机对照试验的二次分析。
Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2.
10
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.在不适合使用华法林的房颤患者中，使用阿司匹林与使用阿哌沙班治疗时的出血情况：在因不耐受或治疗失败而不能使用维生素 K 拮抗剂的房颤患者中，比较阿哌沙班与乙酰水杨酸预防卒中的疗效（AVERROES 试验）。
Stroke. 2012 Dec;43(12):3291-7. doi: 10.1161/STROKEAHA.112.664144. Epub 2012 Oct 2.